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The use of cystoscopy and hydrodistention in the management of interstitial 
cystitis/bladder pain syndrome (IC/BPS) varies widely between providers. Current 









effects of repeated hydrodistention are not well established. We sought to characterize 
the effects of hydrodistention on IC/BPS symptoms as well as bladder capacity. 
METHODS 
We retrospectively queried our institutional records for patients with non-ulcerative 
IC/BPS who underwent hydrodistention over an eleven-year period to obtain 
demographic and clinical factors at the time of diagnosis and treatment. Symptom relief 
and bladder capacity changes were assessed, and multivariable models were used to 
predict response to treatment. 
RESULTS 
There were 328 patients who underwent hydrodistention during the study period, of 
whom 36% received the procedure multiple times, and overall median follow-up was 
38.6 months. Patients with repeated hydrodistentions were more likely to be female, 
have more comorbid pain disorders, and have trialed anticholinergic medications and 
intravesical instillations. No decrease in mean bladder capacity was observed over time 
(p=0.40). Significant decreases in symptom scores were observed following the 
procedure on multiple questionnaires. 
CONCLUSIONS 
Hydrodistention does not decrease bladder capacity even with multiple procedures, and 
measurably improves symptoms in some patients with IC/BPS. Continuing efforts to 











Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic, potentially devastating 
condition characterized chiefly by bladder pressure/discomfort/pain and urinary 
urgency.1 While prevalence estimates vary, available data suggest that roughly 6% of 
women in the United States struggle with this disease, leading to significant suffering as 
well as economic burdens.2-4  
Treatment selection may also be complex, proceeding from dietary modification to oral 
therapy to invasive procedures.5 Current guidance by the American Urological 
Association (AUA) includes cystoscopy with hydrodistention as a third-line treatment 
option in patients for whom conservative management and pharmacological options are 
insufficient.5 However, available data suggests that the use of this procedure varies 
widely across providers.6,7 These variations are likely driven not only by provider 
familiarity with the procedure, but also by a relatively small body of literature assessing 
its efficacy. Historical studies described high rates of complications such as bladder 
rupture, while a recent systematic review found a lack of high quality evidence and 
significant heterogeneity between reports.8,9 
In this context, we sought to characterize our institutional experience with 
hydrodistention in the management of IC/BPS. Specifically, we investigated the 
characteristics of patients undergoing the procedure, complications and readmissions, 
symptom relief as quantified by several common indices, the predictors of symptomatic 
response, and effects of repeated hydrodistention on bladder capacity. Increasing 
provider knowledge of this procedure and highlighting which patients are most likely to 
benefit may allow for more targeted use and improved symptom relief.  










We retrospectively queried our institutional records for all patients undergoing 
cystoscopy and hydrodistention over the eleven-year period from January 2005 to 
December 2015 based on Common Procedural Terminology (CPT) code 52260. These 
records were then reviewed and only patients with a diagnosis of non-ulcerative IC/BPS 
were included. The follow-up interval was calculated as the time from hydrodistention to 
last contact with the Urology department. Patients who only received a single 
hydrodistention and who had less than one year of follow-up were excluded (n=209). 
Baseline and Procedural Characteristics 
Baseline demographic and clinical information as well as prior trials of therapeutic 
agents were obtained from records of clinic visits prior to initial hydrodistention. This 
included age at diagnosis, gender, race and ethnicity, body mass index (BMI), comorbid 
pain disorders (fibromyalgia, irritable bowel syndrome, back pain, joint pain, vulvodynia, 
migraine, temporomandibular joint syndrome), menstrual status, prior oral or intravesical 
therapies, prior pregnancy, history of pelvic surgery, prior implantable neurostimulator 
device, and previous hydrodistention at an outside hospital. Procedural characteristics 
were collected from operative notes and included bladder capacity and intraoperative 
complications. Cystoscopy and hydrodistention is performed by all surgeons at our 
institution in a standardized fashion with deep IV sedation or general anesthetic: 
cystourethroscopy is performed with close examination of the bladder mucosa for 
stigmata of IC/BPS. We retrograde fill the bladder until reaching an intravesical pressure 
of 80 cm of water, which is held for two minutes. The bladder is then drained into a 









undergoes a repeat inspection, and an additional two-minute distention is performed at 
the same pressure. This is followed by routine instillation of 40 milliliters of 2% lidocaine 
into the bladder and a belladonna and opium suppository for pain control. In patients 
who underwent multiple hydrodistention procedures, bladder capacity was tracked 
serially across procedures, and the presence of any incident ulceration was recorded. 
Information regarding unplanned readmissions within 30 days of hydrodistention, as 
well as postoperative complications as described in subsequent clinic notes was 
recorded. 
Outcome 
Our primary outcome was symptomatic improvement as measured by three common 
urological symptom questionnaires: the AUA symptom index, the Michigan Incontinence 
Severity Index (ISI), and the Genitourinary Pain Index (GUPI). The AUA symptom index, 
developed to measure symptoms of benign prostatic hyperplasia, includes measures of 
lower urinary tract symptoms as well as quality of life.10 The ISI specifically assesses 
severity and bother associated with incontinence.11 The GUPI was developed and 
validated to measure urological pain symptoms in both genders, and includes subscales 
for pain symptoms, urinary symptoms, and quality of life.12 Notably, the GUPI was more 
recently developed than the other symptom assessments and so had fewer completed 
responses to analyze. Responses were characterized as preoperative if they were 
recorded in the three months preceding hydrodistention, and postoperative if they were 
recorded in the three months following hydrodistention, which are typically four to eight 









included in the symptomatic improvement portion of analysis if both a preoperative and 
postoperative measurement were available. 
Statistical analysis 
To understand differences in patients who elected to undergo multiple procedures, we 
first compared demographic and baseline clinical characteristics between patients 
undergoing multiple and single hydrodistentions. Continuous variables were assessed 
with Student’s t-tests and the Wilcoxon rank sum, while categorical variables were 
compared with Chi-square tests and Fisher’s exact test. Among patients with multiple 
hydrodistentions, initial and final bladder capacity were compared with paired t-tests. 
Paired t-tests were also used for raw comparisons of preoperative and postoperative 
symptom scores. 
We then created three multivariable, mixed-effects linear models, one for each of our 
symptom questionnaires. The dependent variable for each model was the change from 
preoperative to postoperative symptom score. To account for patients with multiple 
observations, a random intercept effect was included at the patient level. We also 
included independent fixed effects guided by comparisons of patients with multiple vs. 
single hydrodistentions as well as a priori knowledge of which variables were reflective 
of increased IC/BPS severity: comorbid pain conditions, intravesical treatments, gender, 
anticholinergic use. 
All analyses were performed in SAS version 9.4 (SAS Institute, Cary, NC) at the 5% 











There were 328 patients identified who underwent hydrodistention at our institution 
during the eleven-year study period, of whom 119 (36%) received the procedure 
multiple times based on patient request (Table 1). Overall median follow-up was 38.6 
months (range 7.9-128.4). Patients who received multiple procedures were more likely 
to be female, have a higher number of comorbid pain conditions, had prior intravesical 
instillations, and previously undergone hydrodistention at an outside hospital, while they 
were less likely to have previously taken anticholinergic medications. Complication and 
30-day readmission rates were both extremely low. Among those patients who 
underwent multiple hydrodistentions, median number of procedures was 3 (range 2-18) 
and median time between hydrodistentions was 253 days. The patterns of bladder 
capacity change in individual patients over the course of multiple procedures are 
illustrated in Figure 1. There was no significant difference observed between initial and 
final mean bladder capacities (730 cc vs. 750 cc, p=0.40 range 250-1400 cc). 
Comparisons of preoperative and postoperative symptom questionnaires are 
illustrated in Figure 2. AUA symptom and quality of life scores as well as GUPI urinary 
and quality of life scores were all significantly lower following hydrodistention, while 
GUPI pain scores and ISI scores did not differ. Multivariable, mixed-effects linear 
models including gender, comorbid pain disorders, anticholinergic use, and intravesical 











We found that hydrodistention is a safe, well-tolerated procedure with very low 
complication and readmission rates. Undergoing the procedure multiple times did not 
reduce bladder capacity or promote the development of ulcerative disease. Lastly, we 
found significant symptomatic relief following the treatment as measured by several 
validated instruments, but were not able to identify clear predictors of this symptomatic 
improvement. Taken together, these results help to confirm that hydrodistention is a 
worthwhile procedure with significant therapeutic benefits for some patients with severe 
IC/BPS. Additionally, in our clinical experience knowledge of anesthetic capacity can be 
helpful to guide management. When patients have a normal anesthetic bladder capacity 
and consequently an anatomically intact bladder our treatment focuses on pain 
management and bladder retraining, conversely in patients who have a very small 
bladder capacities we focus exclusively on pain. 
Our findings of symptomatic improvement following hydrodistention are 
consistent with previously published results, though differences in technique and 
reporting make it difficult to compare results directly.13-18 Indeed, a recent analysis of the 
literature on hydrodistention found the evidence base overall to be severely lacking, in 
large part due to these differences in reported techniques and outcome measures.9 
However, published studies have reported that 40-70% of patients exhibited at least 
some degree of symptomatic response with varying degrees of durability.13,18 In this 
context our study helps expand the evidence for hydrodistention by adding to the body 
of reports showing a measure of symptomatic benefit following the procedure as well as 
acceptable rates of complications and readmissions. Further, our longitudinal 









concern that post-procedural scarring and fibrosis could lead to reduction in bladder 
capacity beyond that which might be inherent to the disease process. These results are 
consistent with other recent data suggesting that, similar to stratification of IC/BPS into 
ulcerative and non-ulcerative subtypes, bladder capacity may be a unique marker of 
disease severity, prognosis, and comorbidity burden.19-21 The absence of development 
of new Hunner lesions in this cohort combined with anesthetic bladder capacities higher 
than what has been typically reported in the literature regarding ulcerative IC/BPS may 
also lend support to the idea that ulcerative and non-ulcerative IC/BPS could be two 
distinct disease processes. In combination with prior work these results suggest that 
important therapeutic benefits can be achieved through the use of hydrodistention in 
patients suffering from interstitial cystitis. The mechanism for these responses, 
however, has not yet been clearly described. It has long been believed to be related to 
mechanical or ischemic damage to the submucosal nerve endings within the bladder, 
and more recent studies have found measurable changes in urinary biomarkers 
following hydrodistention.14,22 Better characterization of the molecular mechanism of 
hydrodistention could also enable improved identification of patients more likely to 
benefit. 
There are some limitations to this work. Most importantly, as a retrospective 
study these findings are limited in that not all patients had complete symptom 
questionnaire data available from both pre- and postoperative clinic visits. As such, we 
may have been unable to detect smaller differences or accurately identify predictors of 
symptomatic response. This missing data also precluded a meaningful analysis of what 









thorough chart review of the initial clinic visit, these data provide only a snapshot and do 
not fully reflect the dynamic nature of therapeutic choices in IC/BPS. Also, due to the 
previously discussed variability in techniques and use of this procedure across 
providers and institutions these results may not be generalizable to all settings. Among 
the administered symptom questionnaires, the GUPI was only recently incorporated into 
regular clinical visits, which lead to comparatively few patients in this cohort having 
available GUPI results to analyze. This is of particular importance because of the three 
symptom questionnaires included in this analysis the GUPI is the only one designed to 
directly assess the pain symptoms suffered by IC/BPS patients. Due to the inclusion of 
patients who received the procedure multiple times, our findings are likely reflective of a 
self-selected group of patients more likely to feel hydrodistention is of symptomatic 
benefit (i.e. selection bias), thus the effect sizes observed here may be larger than in 
some patient populations. However, the presence of a significant number of such 
patients can itself be interpreted as evidence that the procedure is effective at least for 
some sufferers of IC/BPS. Additionally, an important clinical factor not reflected in this 
analysis is the phenomenon of flares following hydrodistention, in which patients may 
find their IC/BPS symptoms become worse immediately after hydrodistention before 
they subsequently improve from baseline. These flares may make some providers 
hesitate to offer hydrodistention, and it is important that patients be counseled regarding 
this outcome prior to undergoing the procedure. 
Despite these limitations this study adds significantly to the existing literature on 
the use of hydrodistention in IC/BPS. The symptomatic benefits and favorable safety 









clinicians while confirming what others may have already observed in practice. Further, 
our bladder capacity results can ease concerns about the repeated use of this 
procedure in those patients who experience significant therapeutic results. IC/BPS 
remains a difficult condition for both patients and providers; as such it is imperative to 
continue to improve our understanding of the disease pathophysiology and offer 
patients access to the full range of options in the urologist’s armamentarium. 
 
CONCLUSIONS 
We observed symptomatic benefits, excellent safety profile, and no significant 
impact on bladder capacity in this retrospective study of our institutional experience 
using hydrodistention to treat interstitial cystitis/bladder pain syndrome, though we were 
not able to identify clear predictors of symptom response. Ongoing research must work 
to improve the uniformity of outcome measurement and hydrodistention technique, 
while helping to better identify those patients most likely to benefit from the procedure. 
Efforts to further our understanding of the benefits of hydrodistention should help to 
improve the experiences of patients with interstitial cystitis/bladder pain syndrome as 
well as their providers. 
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Figure 1. Change in bladder capacity over multiple hydrodistention procedures. Dots 
represent an individual capacity measurement in an individual patient, and each 
patient’s measurements are linked by a line. 
 




Table 1. Clinical and demographic comparisons between patients who underwent single 










Mean age, years (SD) 39.0 (14.2) 35.5 (15.1) 0.058 
Mean BMI, Kg/m2 (SD) 27.6 (6.5) 27.3 (6.2) 0.60 
Gender, % female 89.5 98.3 <0.01 
Smoker (current or former), % 40.8 39.8 0.44 
History of pregnancy, % 64.9 67.0 0.74 









Postmenopausal, % 30.8 41.4 0.071 
Comorbid pain disorder, % 53.6 61.3 0.17 
   Mean number comorbid pain disorders (SD) 0.9 1.3 0.012 
Oral therapy, % 86.5 83.9 0.53 
   Anticholinergic, % 56.3 38.1 <0.01 
   Tricyclic antidepressant, % 36.4 36.4 0.99 
   Neuropathic pain medication, % 16.0 22.0 0.18 
   Pentosan, % 33.5 36.4 0.59 
   Pyridium, % 33.0 40.7 0.17 
   Hydroxyzine, % 8.7 9.3 0.86 
Intravesical instillation, % 19.1 35.3 <0.01 
Interstim device, % 4.8 6.8 0.45 
History of prior hydrodistention, % 20.1 48.7 <0.001 
Median follow-up time, months (range) 32.3 (12-128.4) 50.5 (7.9-127.2) <0.01 
Complications, % 0.5 0.7 0.78 
30-day readmissions, % 0.5 1.8 0.18 
Median number of hydrodistentions (range) - 3 (2-18) - 
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